AngioDynamics (NASDAQ:ANGO) Issues FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY25 earnings guidance on Thursday morning. The company provided EPS guidance of ($0.42)-($0.38) for the period, compared to the consensus EPS estimate of ($0.41). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $284.37 million. AngioDynamics also updated its FY 2025 guidance to -0.420–0.380 EPS.

AngioDynamics Stock Performance

ANGO opened at $6.37 on Friday. The company has a market cap of $255.15 million, a PE ratio of -1.32 and a beta of 0.65. The stock has a 50-day moving average of $7.51 and a 200-day moving average of $6.62. AngioDynamics has a 52-week low of $5.26 and a 52-week high of $8.25.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.11. The company had revenue of $71.00 million during the quarter, compared to the consensus estimate of $70.86 million. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The firm’s revenue was down 22.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.02 EPS. On average, research analysts predict that AngioDynamics will post -0.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ANGO. HC Wainwright reissued a buy rating and set a $14.00 price objective on shares of AngioDynamics in a research report on Friday, September 20th. Canaccord Genuity Group cut their price objective on AngioDynamics from $18.00 to $13.00 and set a buy rating for the company in a research report on Wednesday, July 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $12.25.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.